Global CD47 (IAP) Market Trends and Forecast Report 2022 | By Players, Types, Applications and Regions

QY Research released a latest market research report on the global and United States CD47 (IAP) market, which is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global CD47 (IAP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

 

Summary

Due to the COVID-19 pandemic, the global CD47 (IAP) market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, CD47 Monoclonal Antibody accounting for % of the CD47 (IAP) global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Solid Tumor was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

 

Global CD47 (IAP) Scope and Market Size

CD47 (IAP) market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global CD47 (IAP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

 

For United States market, this report focuses on the CD47 (IAP) market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

 

For More Information About This Report, Please Enter:

https://us.qyresearch.com/reports/352059/cd47-iap

Segment by Type

CD47 Monoclonal Antibody

CD47 Double Antibody

CD47 Fusion Protein

 

Segment by Application

Solid Tumor

Lymphoma

Others

 

By Company

Gilead

Innovent Biologics

Akeso, Inc

Arch Oncology

ImmuneOncia Therapeutics

I-MAB

Sorrento Therapeutics

Zai Lab

ImmuneOnco

Hengrui

Beijing Mab-works

Hanxbio

ALX Oncology

Surface Oncology

TG Therapeutics

EpicentRx

 

The report on the CD47 (IAP) market covers the following region (country) analysis:

By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

 

The Goal of the Report

  1. To study and analyze the global CD47 (IAP)consumption (value & volume) by key regions/countries, type and application, history data from 2017 to 2022, and forecast to 2028.
  2. To understand the structure of CD47 (IAP)market by identifying its various subsegments.
  3. Focuses on the key global CD47 (IAP)manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
  4. To analyze the CD47 (IAP)with respect to individual growth trends, prospects, and their contribution to the total market.
  5. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges, and risks).
  6. To project the consumption of CD47 (IAP)submarkets, with respect to key regions (along with their respective key countries).
  7. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
  8. To strategically profile the key players and comprehensively analyze their growth strategies.

 

Target Audience

> CD47 (IAP) companies

> Research organizations

> Government Organizations

> Research/Consultancy firms

 

Table of Contents

1 Study Coverage
1.1 CD47 (IAP) Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Introduction
1.2 Global CD47 (IAP) Outlook 2017 VS 2022 VS 2028
1.2.1 Global CD47 (IAP) Market Size for the Year 2017-2028
1.2.2 Global CD47 (IAP) Market Size for the Year 2017-2028
1.3 CD47 (IAP) Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States CD47 (IAP) in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of CD47 (IAP) Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 CD47 (IAP) Market Dynamics
1.4.1 CD47 (IAP) Industry Trends
1.4.2 CD47 (IAP) Market Drivers
1.4.3 CD47 (IAP) Market Challenges
1.4.4 CD47 (IAP) Market Restraints
1.5 Study Objectives
1.6 Years Considered

2 CD47 (IAP) by Type
2.1 CD47 (IAP) Market Segment by Type
2.1.1 CD47 Monoclonal Antibody
2.1.2 CD47 Double Antibody
2.1.3 CD47 Fusion Protein
2.2 Global CD47 (IAP) Market Size by Type (2017, 2022 & 2028)
2.3 Global CD47 (IAP) Market Size by Type (2017-2028)
2.4 United States CD47 (IAP) Market Size by Type (2017, 2022 & 2028)
2.5 United States CD47 (IAP) Market Size by Type (2017-2028)

3 CD47 (IAP) by Application
3.1 CD47 (IAP) Market Segment by Application
3.1.1 Solid Tumor
3.1.2 Lymphoma
3.1.3 Others
3.2 Global CD47 (IAP) Market Size by Application (2017, 2022 & 2028)
3.3 Global CD47 (IAP) Market Size by Application (2017-2028)
3.4 United States CD47 (IAP) Market Size by Application (2017, 2022 & 2028)
3.5 United States CD47 (IAP) Market Size by Application (2017-2028)

4 Global CD47 (IAP) Competitor Landscape by Company
4.1 Global CD47 (IAP) Market Size by Company
4.1.1 Top Global CD47 (IAP) Companies Ranked by Revenue (2021)
4.1.2 Global CD47 (IAP) Revenue by Player (2017-2022)
4.2 Global CD47 (IAP) Concentration Ratio (CR)
4.2.1 CD47 (IAP) Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of CD47 (IAP) in 2021
4.2.3 Global CD47 (IAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global CD47 (IAP) Headquarters, Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Type
4.3.1 Global CD47 (IAP) Headquarters and Area Served
4.3.2 Global CD47 (IAP) Companies Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into CD47 (IAP) Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States CD47 (IAP) Market Size by Company
4.5.1 Top CD47 (IAP) Players in United States, Ranked by Revenue (2021)
4.5.2 United States CD47 (IAP) Revenue by Players (2020, 2021 & 2022)

5 Global CD47 (IAP) Market Size by Region
5.1 Global CD47 (IAP) Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global CD47 (IAP) Market Size by Region (2017-2028)
5.2.1 Global CD47 (IAP) Market Size by Region: 2017-2022
5.2.2 Global CD47 (IAP) Market Size by Region (2023-2028)

6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America CD47 (IAP) Market Size YoY Growth 2017-2028
6.1.2 North America CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific CD47 (IAP) Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific CD47 (IAP) Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe CD47 (IAP) Market Size YoY Growth 2017-2028
6.3.2 Europe CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America CD47 (IAP) Market Size YoY Growth 2017-2028
6.4.2 Latin America CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa CD47 (IAP) Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE

7 Company Profiles
7.1 Gilead
7.1.1 Gilead Company Details
7.1.2 Gilead Business Overview
7.1.3 Gilead CD47 (IAP) Introduction
7.1.4 Gilead Revenue in CD47 (IAP) Business (2017-2022)
7.1.5 Gilead Recent Development
7.2 Innovent Biologics
7.2.1 Innovent Biologics Company Details
7.2.2 Innovent Biologics Business Overview
7.2.3 Innovent Biologics CD47 (IAP) Introduction
7.2.4 Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022)
7.2.5 Innovent Biologics Recent Development
7.3 Akeso, Inc
7.3.1 Akeso, Inc Company Details
7.3.2 Akeso, Inc Business Overview
7.3.3 Akeso, Inc CD47 (IAP) Introduction
7.3.4 Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022)
7.3.5 Akeso, Inc Recent Development
7.4 Arch Oncology
7.4.1 Arch Oncology Company Details
7.4.2 Arch Oncology Business Overview
7.4.3 Arch Oncology CD47 (IAP) Introduction
7.4.4 Arch Oncology Revenue in CD47 (IAP) Business (2017-2022)
7.4.5 Arch Oncology Recent Development
7.5 ImmuneOncia Therapeutics
7.5.1 ImmuneOncia Therapeutics Company Details
7.5.2 ImmuneOncia Therapeutics Business Overview
7.5.3 ImmuneOncia Therapeutics CD47 (IAP) Introduction
7.5.4 ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
7.5.5 ImmuneOncia Therapeutics Recent Development
7.6 I-MAB
7.6.1 I-MAB Company Details
7.6.2 I-MAB Business Overview
7.6.3 I-MAB CD47 (IAP) Introduction
7.6.4 I-MAB Revenue in CD47 (IAP) Business (2017-2022)
7.6.5 I-MAB Recent Development
7.7 Sorrento Therapeutics
7.7.1 Sorrento Therapeutics Company Details
7.7.2 Sorrento Therapeutics Business Overview
7.7.3 Sorrento Therapeutics CD47 (IAP) Introduction
7.7.4 Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
7.7.5 Sorrento Therapeutics Recent Development
7.8 Zai Lab
7.8.1 Zai Lab Company Details
7.8.2 Zai Lab Business Overview
7.8.3 Zai Lab CD47 (IAP) Introduction
7.8.4 Zai Lab Revenue in CD47 (IAP) Business (2017-2022)
7.8.5 Zai Lab Recent Development
7.9 ImmuneOnco
7.9.1 ImmuneOnco Company Details
7.9.2 ImmuneOnco Business Overview
7.9.3 ImmuneOnco CD47 (IAP) Introduction
7.9.4 ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022)
7.9.5 ImmuneOnco Recent Development
7.10 Hengrui
7.10.1 Hengrui Company Details
7.10.2 Hengrui Business Overview
7.10.3 Hengrui CD47 (IAP) Introduction
7.10.4 Hengrui Revenue in CD47 (IAP) Business (2017-2022)
7.10.5 Hengrui Recent Development
7.11 Beijing Mab-works
7.11.1 Beijing Mab-works Company Details
7.11.2 Beijing Mab-works Business Overview
7.11.3 Beijing Mab-works CD47 (IAP) Introduction
7.11.4 Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022)
7.11.5 Beijing Mab-works Recent Development
7.12 Hanxbio
7.12.1 Hanxbio Company Details
7.12.2 Hanxbio Business Overview
7.12.3 Hanxbio CD47 (IAP) Introduction
7.12.4 Hanxbio Revenue in CD47 (IAP) Business (2017-2022)
7.12.5 Hanxbio Recent Development
7.13 ALX Oncology
7.13.1 ALX Oncology Company Details
7.13.2 ALX Oncology Business Overview
7.13.3 ALX Oncology CD47 (IAP) Introduction
7.13.4 ALX Oncology Revenue in CD47 (IAP) Business (2017-2022)
7.13.5 ALX Oncology Recent Development
7.14 Surface Oncology
7.14.1 Surface Oncology Company Details
7.14.2 Surface Oncology Business Overview
7.14.3 Surface Oncology CD47 (IAP) Introduction
7.14.4 Surface Oncology Revenue in CD47 (IAP) Business (2017-2022)
7.14.5 Surface Oncology Recent Development
7.15 TG Therapeutics
7.15.1 TG Therapeutics Company Details
7.15.2 TG Therapeutics Business Overview
7.15.3 TG Therapeutics CD47 (IAP) Introduction
7.15.4 TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
7.15.5 TG Therapeutics Recent Development
7.16 EpicentRx
7.16.1 EpicentRx Company Details
7.16.2 EpicentRx Business Overview
7.16.3 EpicentRx CD47 (IAP) Introduction
7.16.4 EpicentRx Revenue in CD47 (IAP) Business (2017-2022)
7.16.5 EpicentRx Recent Development

8 Research Findings and Conclusion

9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer

 

Access full Report Description, Table of Figure, Chart, FREE sample, etc. please click

https://us.qyresearch.com/reports/352059/cd47-iap

 

Any doubts and questions will be welcome.

 

Customization of the Report:

This report can be customized to meet the client’s requirements. Please contact with us ([email protected]), who will ensure that you get a report that suits your needs.

About Us:

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 15 years’ experience and professional research team in various cities over the world,QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 59,000 clients across five continents. Let’s work closely with you and build a bold and better future.

 

Contact Us

QY Research

E-mail: [email protected]

Tel: +1-626-842-1666(US)   +852-5808-0956 (HK)

Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States

Website: https://us.qyresearch.com

 

Leave a Reply

Your email address will not be published.